BMJ Best Practice

参考文献

关键文献

Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis. 2007;44:568-576.

Rockey DD, Lenart J, Stephens RS. Genome sequencing and our understanding of Chlamydiae. Infect Immun. 2000;68:5473-5479.

参考文章

1.  Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis. 2007;44:568-576.

2.  Hyman CL, Roblin PM, Gaydos CA, et al. The prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: assessment by polymerase chain reaction-enzyme immunoassay and culture. Clin Infect Dis. 1995;20:1174-1178.

3.  Rockey DD, Lenart J, Stephens RS. Genome sequencing and our understanding of Chlamydiae. Infect Immun. 2000;68:5473-5479.

4.  Csango PA, Haraldstad S, Pedersen JE, et al. Respiratory tract infection due to Chlamydia pneumoniae in military personnel. Scand J Infect Dis Suppl. 1997;104:26-29.

5.  Troy CJ, Peeling RW, Ellis AG, et al. Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes. JAMA. 1997;277:1214-1218.

6.  Nakashima K, Tanaka T, Kramer MH, et al. Outbreak of Chlamydia pneumoniae infection in a Japanese nursing home, 1999-2000. Infect Control Hosp Epidemiol. 2006;27:1171-1177.

7.  Kumar S, Kutlin S, Roblin P, et al. Isolation and antimicrobial susceptibilities of chlamydial isolates from Western barred bandicoots. J Clin Microbiol. 2007;45:392-394.

8.  Hyman CL, Augenbraun MH, Roblin PM, et al. Asymptomatic respiratory tract infection with Chlamydia pneumo­niae TWAR. J Clin Microbiol. 1991;29:2082-2083.

9.  Falsey AR, Walsh EE. Transmission of Chlamydia pneumoniae. J Infect Dis. 1993;168:493-496.

10.  Gray GC, Witucki PJ, Gould MT, et al. Randomized, placebo-controlled clinical trial of oral azithromycin prophylaxis against respiratory infections in a high-risk young adult population. Clin Infect Dis. 2001;33:983-989.

11.  Kohlhoff SA, Hammerschlag MR. Treatment of chlamydial infections: 2014 update. Expert Opin Pharmacother. 2015;16:205-212.

12.  Hammerschlag MR, Roblin PM. Microbiologic efficacy of levofloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrob Agents Chemother. 2000;44:1409.

13.  Hammerschlag MR, Roblin PM. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Int J Antimicrob Agents. 2000;15:149-152.

14.  Block S, Hedrick J, Hammerschlag MR, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in community acquired pneumonia in children: comparative safety and efficacy of clarithromycin and erythromycin suspensions. Pediatr Infect Dis J. 1995; 14:471-477.

15.  Harris J-A, Kolokathis A, Campbell M, et al. Safety and efficacy of azithromycin in the treatment of community acquired pneumonia in children. Pediatr Infect Dis J. 1998;17:865-871.

16.  Roblin PM, Hammerschlag MR. Microbiologic efficacy of azithro-mycin and susceptibility to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community acquired pneumonia. Antimicrob Agents Chemother. 1998;42:194-196.

17.  Hammerschlag MR, Chirgwin K, Roblin PM, et al. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis. 1992;14:178-182.

18.  Emre U, Roblin PM, Gelling M, et al. The association of Chlamydia pneumoniae infection and reactive airway disease in children. Arch Pediatr Adolesc Med. 1994;148:727-732.

19.  Riska PF, Kutlin A, Ajiboye P, et al. Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae. Antimicrob Agents Chemother. 2004;48:3586-3590.

使用此内容应接受我们的免责声明